Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma.
Mora J, Castañeda A, Colombo MC, Gorostegui M, Gomez F, Mañe S, Santa-Maria V, Garraus M, Macias N, Perez-Jaume S, Muñoz O, Muñoz JP, Barber I, Suñol M.
Mora J, et al. Among authors: munoz o, munoz jp.
Cancers (Basel). 2021 Mar 12;13(6):1264. doi: 10.3390/cancers13061264.
Cancers (Basel). 2021.
PMID: 33809255
Free PMC article.